Silver Spring. Maryland–(ENEWSPF)–May 31, 2016. On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA.
PBC is a chronic, or long lasting, disease that causes the small bile ducts in the liver to become inflamed, damaged…
